Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03067272 · ClinicalTrials.gov registry record · NA

Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception

A NA study of Contraception, sponsored by Femasys.

Completed
Registry status
NA
Development phase
49
Enrollment target
4
Study locations

NCT03067272 is a NA study of Contraception that has completed, run by Femasys. The registered enrollment target is 49 participants, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03067272, a NA study of Contraception, has completed, sponsored by Femasys.

COMPLETED
Registry status
NA
Development phase
49 participants
Enrollment target
4
Study locations

Study Summary

Prospective, multi-center, pilot study evaluating the safety of the FemBloc® Permanent Contraceptive System for female sterilization in preventing pregnancy.

Conditions Studied

Interventions

  • DEVICE FemBloc® Permanent Contraceptive System

Study Locations (4)

Florida

  • Altus Research Inc. - Lake Worth

New York

  • New York Presbyterian Hospital - Columbia University Medical Center - New York

North Carolina

  • University of North Carolina, Chapel Hill - Chapel Hill

Tennessee

  • Chattanooga Medical Research - Chattanooga

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2017-03-15
Est. Completion 2023-03-14
Phase NA

Sponsor

Femasys

5 total trials

What the Registry Record Tells You About NCT03067272

The ClinicalTrials.gov registry entry for NCT03067272 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (89% lower). The listed sponsor is Femasys, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which FemBloc® Permanent Contraceptive System is the first listed.

NCT03067272 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, New York, North Carolina.

Frequently Asked Questions

What is clinical trial NCT03067272 about?

NCT03067272 is a clinical study titled "Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception". Prospective, multi-center, pilot study evaluating the safety of the FemBloc® Permanent Contraceptive System for female sterilization in preventing pregnancy.

What is the current status of trial NCT03067272?

This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2017-03-15. Estimated completion is 2023-03-14.

What conditions does trial NCT03067272 study?

This clinical trial studies the following conditions: Contraception.

What interventions are being tested in trial NCT03067272?

The interventions under investigation include: FemBloc® Permanent Contraceptive System (DEVICE).

Who is sponsoring clinical trial NCT03067272?

This trial is sponsored by Femasys, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03067272 being conducted?

This trial has 4 study locations across Florida, New York, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Contraception

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.